Andrew A. Radin
CEO, twoXAR Pharmaceuticals

Every year, for the past 39 years, the J.P. Morgan Healthcare Conference has been one of the most reliable predictors of our industry’s health. It’s a gauge of industry innovation, deal making, funding and overall sentiment about the value of the pharmaceutical market.

However, this year was obviously different. We were faced with unprecedented economic decline and an industry seemingly entirely focused on COVID-19. Expectations were tempered for a lot of companies as to what impact this pandemic and this economy will have on funding new pharmaceutical innovation.

We attended this year’s virtual meeting…

Andrew A. Radin
CEO, twoXAR Pharmaceuticals

Without a doubt, 2020 has been a trying year. The pandemic has touched every business and every human on earth in different ways. And despite all of its tragic outcomes, it has starkly reminded me that we work in one of the most exciting and innovative industries in the world — the life sciences industry.

I am writing this at a time when the US FDA has just issued an emergency use authorization for a vaccine using new technology, against a new pathogen. We are also just days away from another potential FDA vaccine…

by: Andrew A. Radin
CEO, twoXAR

I recently authored an article for MedCity News discussing the hype surrounding AI, especially as it relates to fighting COVID-19. Since the very beginning of this pandemic, researchers and pharmaceutical companies have been working around the clock to find treatments and, more importantly, develop a vaccine. And, as usual, there has been a plethora of media articles and peer-reviewed journal publications discussing how AI can support these efforts. A lot of that is driven by AI companies themselves, or companies that apply AI to discover treatments.

When this virus became a serious public threat…

by: Aaron Daugherty

This week we are celebrating the release of the 250th version of our drug discovery software platform! I am so incredibly proud of the improvements our software team is constantly pushing out; it is the foundation that supports twoXAR’s dedication to rapidly identifying treatments for patients in need.

Our platform makes drug discovery and development faster and with fewer false positives. To build this platform, we use an approach that tightly couples scientists and software developers to make R&D faster, more accurate, and/or cheaper. Our scientists work with our software team to share how they work through…

by: Andrew A. Radin
CEO, twoXAR

I met Tim for the first time almost three years ago and I remember our meeting well. He furrowed his brow slightly as I explained the details on how our technology creates computational models of pathogenesis to derive new understanding of disease, and then identifies hits to test those new hypotheses within weeks instead of years. I’ve come to learn that the furrowed brow appears when the gears start turning in Tim’s head. And what exceptional gears they are.

by: Andrew A. Radin
CEO, twoXAR

Today I received an email from an influencer in the life science community. Paraphrasing a bit, here’s what she said:

“We have reviewed nearly 400 companies in this space — so much going on! How are you differentiated from others?”

Rather than email her individually, I viewed this as the perfect opportunity to share how twoXAR Pharmaceuticals is different. Our work is like nothing else.

We are a pharmaceutical company that uses AI in the discovery of new medications

To begin to answer the question we must start with differentiating ourselves against the hundreds…

by: Andrew A. Radin
CEO, twoXAR

As usual, there’s a lot of news coming out of the 38th Annual JPMorgan Chase Healthcare Conference. And machine learning’s ability to support the pharmaceutical research and development process is no exception. There have been dozens of presentations on this very topic, and even more companies pitching the promise of artificial intelligence (AI). But, one thing is very clear: More education is needed about how AI can support pharmaceutical research.

The JPMorgan Chase conference is centrally a finance and investor meeting. And what we’ve seen so far is that healthcare investors continue to bet…

Nine new projects, three announced partnerships

by: Andrew A. Radin
CEO, twoXAR

Like many of you, I am winding down my work week to prepare for the holiday season. As a new decade approaches it is a good time to reflect on the events of the past year.

2019 saw tremendous growth for twoXAR. We launched nine new disease areas, expanding to new disease programs in our focus areas of ophthalmology, immunology & inflammatory, oncology and metabolic. We ended the year with eighteen total diseases in our portfolio, six of which have been out licensed.